• Explore /
  • Poster
  • / NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)— Safety interim analysis.

NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)— Safety interim analysis.

Abstract Poster

Authors

null

Waldemar Uhl

Ruhr-University Bochum, St. Josef Hospital, Bochum, Germany

Waldemar Uhl , Thomas Jens Ettrich , Anke C. Reinacher-Schick , Hana Algül , Helmut Friess , Marko Kornmann , Alexander Koenig , Michael Ghadimi , Uwe A Wittel , Eike Gallmeier , Kai Wille , Michael Geissler , Carl Christoph Schimanski , Nicole Prasnikar , Andrea Tannapfel , Lukas Perkhofer , Andreas W. Berger , Thomas Seufferlein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02047513

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4128)

DOI

10.1200/JCO.2019.37.15_suppl.4128

Abstract #

4128

Poster Bd #

233

Abstract Disclosures

Similar Posters

First Author: Thomas Jens Ettrich

First Author: Thomas Jens Ettrich

First Author: Derek B. Grose

First Author: Sina Buchholz